

重组人LR3胰岛素样生长因子(LR3-IGF-I)


LR3 Insulin-Like Growth Factor-I, Human, Recombinant

Cat. No.: MA1315-1 Size: 10 μ g

Source:	E.coli
Description:	Recombinant Human LR3 Insulin-Like Growth Factor-I is produced by our E.coli expression system and the target gene encoding Gly49-Ala118 is expressed.
Accession:	P05019
Known As:	Insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1
Predicted Mol Mass:	9.1 KDa
Apparent Mol Mass:	11 KDa, reducing conditions
Endotoxin:	< 0.01 EU/ μ g as determined by LAL test.
Formulation:	Lyophilized from a 0.2 μ m filtered solution of 20mM NaAc-HAc, 4% Mannitol, pH 4.5.
Reconstitution:	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 μ g/ml. Dissolve the lyophilized protein in 50mM Acetic Acid. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Shipping:	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Storage:	Lyophilized protein should be stored at $\leq -20^{\circ}\text{C}$, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8 $^{\circ}\text{C}$ for 2-7 days. Aliquots of reconstituted samples are stable at $\leq -20^{\circ}\text{C}$ for 3 months.
Background:	Insulin-like growth factor I (IGF1) belongs to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contains the N- and C-terminal propeptide regions. Mature human IGF-I consisting of 70 amino acids has 94% identity with mouse IGF-I and exhibits cross-species activity. IGF-1 binds IGF-IR, IGF-IIR, and the insulin receptor and plays a key role in cell cycle progression, cell proliferation and tumor progression. IGF-1 expression is regulated by growth hormone. R3 IGF-1 is an 83 amino acid analog of IGF-1 comprising the complete human IGF-1 sequence with the substitution of an Arg (R) for the Glu(E) at position three, hence R3, and a 13 amino acid extension peptide at the N terminus. R3 IGF-1 has been produced with the purpose of increasing biological activity. R3 IGF-1 is significantly more potent than human IGF-I in vitro.



Purity-SDS-PAGE:



Greater than 95% as determined by reducing SDS-PAGE.

